ORAGENICS INC (OGEN): Nasdaq/NYSE listing notice — Oragenics receives NYSE American deficiency notice for low stock price; must cure by June 19, 2023

ORAGENICS INC

NYSE American notified OGEN that its 30-day average stock price fell below $0.20, violating Section 1003(f)(v).
Stock will trade with 'BC' designation indicating non-compliance; delisting not immediate.
Company has until June 19, 2023 to demonstrate sustained price improvement or effect a reverse stock split.
If not cured by deadline, NYSE American may commence delisting proceedings, threatening liquidity and listing status.
Company intends to monitor price and consider options; no impact on business operations or SEC reporting requirements.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ORAGENICS INC received a nyse_american noncompliance notice notice regarding other (rules 1003(f)(v), 1009).

Exchange: nyse american
Notice: noncompliance notice
Rules: 1003(f)(v), 1009

Exact text from the filing

December 19, 2022, Oragenics, Inc. (the “Company”) received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide (“Section 1003(f)(v)”) because its shares of common stock have been selling for a substantial period of time at a low price per share, which NYSE American determined to be a 30-trading-day average price of less than $0.20 per share. The Notice has no immediate effect on the listing or trading

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ORAGENICS INC filing history →

Source: SEC EDGAR

accession 0001493152-22-036020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.